New antidepressants or more of the same? Effective antidepressant drugs have been available for half a century since the fi rst monoamine oxidase inhibitor (MAOI), isoniazid, and the prototype tricyclic antidepressant (TCA), imipramine, were introduced into therapy (Leonard and Spencer 1990). The use of MAOIs declined when reports appeared of hypertensive crises associated with ingestion of dietary tyramine, and the TCAs, despite their shortcomings in safety and tolerability, became the mainstays of treatment. A second generation of drugs of various classes was developed with diverse chemical structures and different mechanisms of action (Pinder and Wieringa 1993) , of which the most widely prescribed have been the selective serotonin reuptake inhibitors (SSRIs). Although modern drug discovery technologies like combinatorial chemistry and high-throughput screening have made less likely the identifi cation of truly novel agents (Pinder 2001) , new agents and biological targets continue to be investigated (Bosker et al 2004) . Psychological treatments, including cognitive and interpersonal therapies, also have their place in the acute and maintenance treatment of depression (DeRubels et al 2005).
lack of sedation and minimal effects on sexual function make it suitable for general use (Kennedy and Eisfeld 2007) . Its potential role in sleep disorders and jet lag have hardly been explored so far.
Neither of these drugs represents a breakthrough in the treatment of depression, but are the latest incremental advances in our ability to address the most common mental health problem of our age. We still need antidepressants that act faster to produce more response and remission; the gains of the last decades since the introduction of MAOIs and TCAs have been more in safety and tolerability than in effi cacy. Improvements in diagnosis and our emerging ability to characterize different forms of depression in biological terms may ultimately help to develop more targeted treatments of greater effi cacy.
